Mankind Pharma IPO | Date, Price Band, Allotment Link

Mankind Pharma IPO

Mankind Pharma IPO


Mankind Pharma Ltd produces and sells consumer healthcare items in addition to pharmaceutical formulations for a range of acute and chronic therapeutic conditions.

The company’s primary market of concentration is the domestic market, which accounted for 97.6% of all operating revenue in the fiscal year 2022.

In India, it is the fourth-largest pharmaceutical firm by domestic sales.

Mankind Pharma runs 25 production plants all throughout India and has a national marketing presence. Also, it has one of the biggest medical representative distribution networks in the Indian pharmaceutical industry.

The complete public offering of Mankind Pharma Ltd is an OFS ( Offer For Sale ) from current shareholders to sell equity shares worth up to Rs. 4,326 crores.

Mankind Pharma IPO

IPO date25 Apr 2023 – 27 Apr 2023
Listing date09 May 2023
Price rangeRS 1026 – 1080
Minimum order quantity13

IPO Schedule

Issue Period25th April to 27th April 2023
Deadline for accepting UPI mandateUntil 5 PM on the issue closing day
Finalization of Allotment3rd May 2023
Initiation of Refunds4th May 2023
Credit of Shares8th May 2023
Date of Listing9th May 2023
Mandate end date12th May 2023
Anchor Investors Lock-In End Date27th May 2023

Financial Information

Financial YearTotal Assets (₹ crores)Total Revenue (₹ crores)Profit After Tax (₹ crores)EBITDA (₹ crores)ROCE
March 31, 20205,073.295,865.231,056.151448.3535.86%
March 31, 20216,372.636,214.431,293.031659.7830.41%
March 31, 20229,147.747,781.561,452.962003.8025.50%

Mankind Pharma IPO Allotment Link

You can check the allotment status for the Mankind Pharma Limited IPO on the website of the Registrar and Transfer agent.

Alternatively, you can also check the allotment status of Mankind Pharma Ltd on the NSE website.


If you like this blog please share and comment thanks.

This blog contains no recommendations. Please consult a financial advisor. This content is published for educational purposes.